-
Innovent announced the preliminary results of the Phase Ia dose escalation study of IBI315 (anti-Her2/PD-1 bispecific antibody) in patients with advanced solid tumors at the CSCO annual meeting in 2021
Time of Update: 2021-10-10
San Francisco, USA and Suzhou, China September 29, 2021/PRNewswire/ - Cinda Biopharmaceutical Group (Hong Kong Stock Exchange stock code: 01801), a company dedicated to R&D, production and sales for the treatment of tumors, metabolic diseases, A biopharmaceutical company that is an innovative drug for major diseases such as autoimmunity will report the preliminary results of a phase Ia clinical study of IBI315 (the world's first anti-Her2/PD-1 bispecific antibody) at the 2021 China Clinical Oncology Conference (CSCO) .
-
Children's medicine has become a new blue ocean, and the domestic pharmaceutical company market war is about to come
Time of Update: 2021-10-10
However, as the issue of children’s medication has become a livelihood issue that the country attaches great importance to, in order to increase the enthusiasm of manufacturers for research and development, in recent years, the National Food and Drug Administration, the National Health Commission, and the Medical Insurance Bureau have successively introduced a series of policies and measures to encourage Development, production and sales of children's drugs .
-
Which segments of the pharmaceutical industry will be immune to centralized procurement?
Time of Update: 2021-10-10
The data shows that the domestic pharmaceutical equipment market has exceeded 100 billion yuan in 2020, and it is expected to continue to maintain an industry growth rate of about 14% in the future.
-
AstraZeneca China’s Western Headquarters was officially opened to facilitate the development of a healthy ecological integration in the Western Region
Time of Update: 2021-10-10
"Lai Minglong, General Manager of AstraZeneca China, gave an opening speech at the sub-forum of "New Development and New Ideas for Internet Hospitals"Take root in the west and deepen China's commitmentAstraZeneca’s Western China Headquarters, which was grandly unveiled at this summit, is located in the Frontier Medical Center of Chengdu High-tech Zone.
-
Under the normalization of drug sampling inspections, the quality of products of such enterprises still needs to be improved
Time of Update: 2021-10-10
It is understood that on September 26, the Guangdong Provincial Food and Drug Administration issued a phase 2 drug random inspection information notice, and a total of 9 batches of drugs did not meet the drug standards .
-
Guo Qiyong, chairman of Northeast Pharmaceutical, resigns
Time of Update: 2021-10-10
On September 28, Northeast Pharmaceutical issued an announcement stating that the company’s board of directors received a written resignation report from Mr.
Guo Qiyong resigned, he still served as a director of the company's eighth board of directors, chairman of the strategy committee, and a member of the nomination committee .
-
The implementation of the Regulations on Traditional Chinese Medicine of Guangdong Province supports Guangdong to promote cooperation in the Chinese medicine industry in the Greater Bay Area
Time of Update: 2021-10-10
The "Regulations of Guangdong Province on Traditional Chinese Medicine" make provisions on improving the service system of traditional Chinese medicine, strengthening the protection of traditional Chinese medicine and industrial development, strengthening the training of traditional Chinese medicine talents and technological innovation, promoting the inheritance and cultural dissemination of traditional Chinese medicine, and improving safeguard measures and supervision and management .
-
The development of Chinese medicine is included in the right to health, and the speed of industrial upgrading will continue to accelerate
Time of Update: 2021-10-10
. For example, from the national level to the local level, the overall plan for the development of traditional Chinese medicine shows that the speed of innovation, research and development and industrial upgrading of Chinese medicine enterprises is accelerating and entering the golden period of development .
-
There are still many difficulties in the development of the domestic innovative drug industry, how to break the situation
Time of Update: 2021-10-10
In recent years, as the situation and policy environment have changed, innovation has become a necessary means for local pharmaceutical companies to develop upward . In this context, the research an
-
Hausen's Class 1 new drug "Peihuaxi hippocampus" declares for listing
Time of Update: 2021-10-10
Article source: Medical Rubik's Cube InfoAuthor: Shi BeiOn September 30, the official website of CDE showed that the listing application for Peihuaxi hippocampal peptide injection, a new class 1 drug of Hausen Pharmaceuticals, was accepted by the State Food and Drug Administration .
-
Expert review ends 2021 national talks drugs have been confirmed!
Time of Update: 2021-10-10
On September 28, the National Medical Insurance Administration issued new news: In accordance with the "2021 National Medical Insurance Drug Catalog Adjustment Work Plan", the National Medical Insuran
-
The "authorized introduction" model of innovative drugs is gaining popularity, with more than 90 projects in the year
Time of Update: 2021-10-10
On September 16, Saisheng Pharmaceuticals announced that the company has reached a cooperation and licensing agreement with Tarveda Therapeutics, which will serve as the latter's exclusive partner in the development, production and commercialization of Greater China (including China, Hong Kong, Macau and Taiwan) New product portfolio of small molecule conjugated drugs .
-
With cost control becoming the focus of the development of Chinese medicine companies, the pharmaceutical machinery industry may become a major boost
Time of Update: 2021-10-10
In fact, in order to help traditional Chinese medicine companies reduce costs and increase efficiency, and reduce cost pressure, many pharmaceutical companies have begun to accelerate innovation and upgrade equipment .
-
Many places are continuing to strengthen the supervision of medical device products, and machinery companies will face major challenges
Time of Update: 2021-10-10
In addition, the Anhui Provincial Food and Drug Administration has also continued to promote the quality and safety supervision of medical devices for epidemic prevention and control in the province in the near future, and organized supervisors to carry out centralized unannounced inspections of 11 medical device manufacturers .
-
In order to achieve transformation and upgrading, the Chinese medicine industry is accelerating into the era of intelligent manufacturing
Time of Update: 2021-10-10
In general, China's traditional Chinese medicine industry is currently developing in a high-quality direction through continuous innovation and the promotion of the integration of advanced information technology and traditional Chinese medicine .
-
Two pharmaceutical companies completed financing within the month to accelerate the development of First-in-Class innovative drugs
Time of Update: 2021-10-10
In the past month, two pharmaceutical companies completed financing to accelerate the development of First-in-Class innovative drugs .
On September 13th, Yinming Biotechnology announced that it has recently completed nearly 50 million US dollars in A+ round of financing .
-
Under the accelerated transformation and upgrading of the pharmaceutical industry, how does the pharmaceutical machinery industry fight a "cooperation war"
Time of Update: 2021-10-10
It is worth noting that in recent years, with the increasing aging of our country, the continuous improvement of residents' living standards, and the advancement of medical reform, the domestic pharmaceutical market has ushered in rapid development, while industrial transformation and upgrading have also begun to accelerate .
-
Over 30 new drugs approved in China in the third quarter of 2021!
Time of Update: 2021-10-10
At the same time, a number of new anti-cancer drugs were approved in China for the first time, including the second-generation proteasome inhibitor carfilzomib jointly developed by Amgen and BeiGene, and anti-GD2 introduced by BeiGene from EUSA Pharma.
-
Hengrui's Fluzoparib is approved for clinical treatment of colorectal cancer with bevacizumab
Time of Update: 2021-10-10
On September 28, Hengrui Medicine announced that the PARP inhibitor fluzoparib has been approved for a phase Ib/III clinical trial, combined with bevacizumab versus capecitabine and bevacizumab for unresectable or metastatic disease First-line maintenance treatment for colorectal cancer .
-
Various places are vigorously promoting the development of the biomedical industry, and this market may usher in a big explosion!
Time of Update: 2021-10-10
In addition to Jiangsu Province, the Hainan Provincial Food and Drug Administration has also issued the "Notice on Further Optimizing Services to Support the High-Quality Development of the Biopharmaceutical Industry", and introduced a total of 12 optimization service measures, from promoting the development of industrial clusters and encouraging the undertaking of the production of pharmaceuticals and medical devices.
